OncoMethylome Appoints Dr. Jan Groen as CEO
(Thomson Reuters ONE) -
Liege (Belgium) - April 12, 2010, 8:00 CET - OncoMethylome Sciences SA announced
today that its board of directors has named Dr. Jan Groen to serve as the
company's chief executive officer. The company also reports that all agenda
items for the Extraordinary General Shareholders' meeting held April 6 were
unanimously approved by the quorum of shareholders present and represented at
the meeting.
Dr. Jan Groen, has more than 25 years of experience in the clinical diagnostic
industry, with a focus on emerging technologies, product development and
commercialization. Dr. Groen was previously the president of Agendia Inc. and
COO of Agendia B.V. and was responsible for their United States and European
diagnostic operations. Prior to this, he served as vice president of research
and development at Focus Diagnostics Inc., a subsidiary of Quest Diagnostics, in
California. Dr. Groen has held numerous management and scientific positions at
ViroClinics B.V., the Erasmus Medical Center, and Akzo-Nobel. Dr. Jan Groen is a
supervisory board member of IBL International B.V.
Dr. Bob Timmins, OncoMethylome's chairman, said that the OncoMethylome board
unanimously selected Dr. Groen based on his extensive experience of managing
diagnostic product development and commercial operations in both the United
States and in Europe, as well as his strong executive and personal qualities.
"Our search for a CEO to lead the company in its next phase of development and
to accelerate the commercialization of our pipeline of products has been
thorough. A screening team of board members evaluated a broad range of
candidates and interviewed many individuals. Dr. Groen was our top choice" said
Dr. Timmins.
"Dr. Jan Groen has a reputation for being both a strategic visionary and a
results-driven leader. At Agendia and at Quest Diagnostics, he has managed
products in areas similar to those of OncoMethylome, such as tests for
colorectal and breast cancers. Dr. Groen's hands-on experience in dealing with
several critical factors in our industry - such as conducting and prioritizing
research projects, validating products in clinical trials, seeking and obtaining
regulatory approval of new tests, and obtaining insurance and government
reimbursement for medical tests - make him a perfect fit for the company's
needs" comments Dr. Timmins.
"I am very excited to join the company at this critical time and I very much
look forward to work with OncoMethylome's team to realize its ambitious goals
for the development and growth of molecular diagnostic products to target the
global cancer diagnostic market." said Dr. Jan Groen.
Dr. Groen will start on April 26 and join the OncoMethylome board immediately.
"Dr. Groen is an excellent choice as CEO for OncoMethylome and I will support
him and the company going forward" stated Mr. Herman Spolders. Mr. Spolders
retired as CEO in 2009 and will now also retire from his OncoMethylome Board
position effective April 26, 2010. Herman Spolders will stay on as an advisor
to the company, but desires to spend more time on other activities.
The Board is thankful to Herman Spolders for all the work and effort he put into
developing the company and its products over the past 7 years. "Herman Spolders
was key to identifying opportunities and developing products based on a new
technology, and we are glad to be able to count on his continued support going
forward" stated Dr. Timmins.
Dr. Jan Groen will succeed Mr. Philip Devine, a co-founder of the company, who
has been chief financial officer since 2003 and has also been the interim chief
executive officer. Philip Devine will remain CFO. OncoMethylome will continue
the changes that have been launched by Mr. Devine in the last months, including
the focus on a core set of products, a reduction of the operating costs of the
company, and the focus on the United States market.
On April 6, OncoMethylome held an Extraordinary General Shareholders Meeting, as
communicated on March 11 and 12. All proposed agenda items were unanimously
approved by the quorum of shareholders present and represented at the meeting.
To download this press release as a PDF, click here: Press Release PDF
About OncoMethylome Sciences
OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is
a molecular diagnostics company developing gene methylation tests to assist
physicians in effectively detecting and treating cancer. Specifically, the
company's tests are designed to help the physician (i) accurately detect cancer
in early stages of cancer development, (ii) predict a patient's response to drug
therapy, and (iii) predict the likelihood of cancer recurrence.
The company collaborates with leading international molecular oncology research
centers, such as The Johns Hopkins University, and has a number of commercial
and collaborative partnerships with LabCorp, Schering-Plough Corp.,
GlaxoSmithKline Biologicals , Millipore Corporation's BioScience Division,
Merck KGaA and Qiagen. OncoMethylome's products are based on methylation
technology invented by Johns Hopkins University (USA).
Established in January 2003, OncoMethylome has offices in Europe and in Durham,
NC (USA).
For more information please contact:
Philip Devine
Tel. (+32) 4.364.20.70
ir(at)oncomethylome.com
www.oncomethylome.com
[HUG#1402208]
2010-4-12 New CEO PR - ENG - Final: http://hugin.info/137314/R/1402208/356831.pdf
Press Release PDF: http://hugin.info/137314/R/1402208/356829.pdf
Unternehmensinformation / Kurzprofil:
Datum: 12.04.2010 - 08:01 Uhr
Sprache: Deutsch
News-ID 18827
Anzahl Zeichen: 0
contact information:
Town:
Liège
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 865 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"OncoMethylome Appoints Dr. Jan Groen as CEO"
steht unter der journalistisch-redaktionellen Verantwortung von
OncoMethylome Sciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
